Urgent safety recall for eye care products
(WJW) – Multiple over-the-counter eye care products are being voluntarily recalled nationwide after a U.S. Food and Drug Administration audit revealed serious manufacturing violations.
BRS Analytical Service announced the consumer-level recall of five ophthalmic solutions due to violations of current good manufacturing practices. Though the specific health hazards remain undetermined, the deviations raise concerns that the products may not meet quality standards, making potential risks to patients impossible to rule out.
Rethink when you fix your dog, new study says
The recalled products include:
Artificial Tears Ophthalmic Solution (NDC# 50268-043-15)
Carboxymethylcellulose Sodium Ophthalmic Gel 1% (NDC# 50268-066-15)
Carboxymethylcellulose Sodium Ophthalmic Solution (NDC# 50268-068-15)
Lubricant Eye Drops Solution (NDC# 50268-126-15)
Polyvinyl Alcohol Ophthalmic Solution (NDC# 50268-678-15)
Click here to sign up for recall alerts
These items were distributed between May 26, 2023, and April 21, 2025. Click here for the full lot number list.
Consumers are urged to stop using these products immediately.
While there have been no confirmed adverse events linked to the products so far, experts caution that eye drops, especially those intended to treat dryness or irritation, must meet strict sterility and formulation standards to avoid serious complications such as eye infections or vision loss.
Bay Village lacrosse player dies after critical injury during game
Customers are instructed to complete the 'Quantity to Return' section on the recall notice and email it to customerservice@avkare.com or fax it to 931-292-6229, even if they no longer possess the product.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
More Than 40,000 Pounds of Shrimp Recalled Over Potential Health Risk
If you're a frequent consumer of seafood, it might be time to check what's in your fridge. According to a statement issued by the U.S. Food and Drug Administration, 44,550 pounds of Bornstein Seafoods' Cooked and Peeled Ready-to-Eat Coldwater Shrimp Meat have been recalled due to the potential contamination of Listeria monocytogenes, the bacteria that causes Listeria. The product was distributed in states like California, Oregon, Washington, and British Columbia (Canada), and may have been further distributed nationwide. Bornstein Seafoods, located in Bellingham, Washington, urges consumers to return the product immediately and receive a full refund. Listeria monocytogenes, the organism that causes Listeria, can sometimes cause fatal infections in young children, elderly people, pregnant women, and those with weakened immune systems. Healthy individuals might experience common symptoms such as fever, headaches, stiffness, nausea, abdominal pain, and diarrhea. No illnesses have been reported to date. To ensure you haven't purchased the affected products, read on for the full product listing—along with their Universal Product Code (UPC) and Lot number. Fzn Shrimp Meat 250/350 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19008 Fzn Shrimp Meat 250/350 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, A19009 Fzn Shrimp Meat 250/350 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, P11710 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19009 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19019 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19026 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19030 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19032 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19037 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19039 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, A18989 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, A19006 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, A19007 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, P11709 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, P11710 If you notice symptoms associated with Listeria, contact your healthcare provider immediately. For further information or inquiries, you can contact the company at andrew@ Read the original article on Real Simple
Business Wire
10 hours ago
- Business Wire
U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA ® (zanubrutinib) for all five approved indications. BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines of therapy in the U.S., and for the first time, has become the overall BTK inhibitor market share leader. 1 BRUKINSA tablets have the same efficacy and safety as BRUKINSA capsules based on the results of two single-dose, open-label, randomized Phase 1 crossover studies of healthy adults designed to establish bioequivalence. BRUKINSA is the only BTK inhibitor to offer the flexibility of once or twice daily dosing, with the ability to tailor the schedule to patient needs. It also continues to be the only BTK inhibitor with recommended dosing for severe hepatic impairment. 'BRUKINSA's leadership in the U.S. underscores the trust physicians and patients have placed in its differentiated clinical profile,' said Matt Shaulis, General Manager of North America, BeOne. 'With this new tablet formulation, we are making treatment simpler and more convenient—an important step forward for patients facing certain B-cell cancers.' The recommended dose of BRUKINSA remains at 320 mg daily. The new BRUKINSA tablets are 160 mg each, allowing patients to take two tablets daily rather than four of the current 80 mg capsules. Additionally, BRUKINSA tablets are smaller than the capsules and have a film coating, making them easier to swallow. The BRUKINSA tablets will replace capsules starting in October 2025. The European Medicines Agency is currently reviewing a Type II variation marketing authorization application (MAA) for the new tablet formulation of BRUKINSA in all currently approved indications, with approval expected later this year. About BRUKINSA ® (zanubrutinib) BRUKINSA is an orally available, small molecule inhibitor of Bruton's tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues. BRUKINSA has the broadest label globally of any BTK inhibitor and is the only BTK inhibitor to provide the flexibility of once or twice daily dosing. Additionally, BRUKINSA is also the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study. The global BRUKINSA clinical development program includes about 7,100 patients enrolled in 30 countries and regions across more than 35 trials. BRUKINSA is approved in more than 75 markets in at least one indication, and more than 200,000 patients have been treated globally. U.S. Indications and Important Safety Information for BRUKINSA (zanubrutinib) INDICATIONS BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Waldenström's macroglobulinemia (WM). Mantle cell lymphoma (MCL) who have received at least one prior therapy. Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. The MCL, MZL and FL indications are approved under accelerated approval based on overall response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. IMPORTANT SAFETY INFORMATION Warnings and Precautions Hemorrhage Fatal and serious hemorrhage has occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher hemorrhage including intracranial and gastrointestinal hemorrhage, hematuria, and hemothorax was reported in 3.8% of patients treated with BRUKINSA in clinical trials, with fatalities occurring in 0.2% of patients. Bleeding of any grade, excluding purpura and petechiae, occurred in 32% of patients. Bleeding has occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Coadministration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage. Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days before and after surgery depending upon the type of surgery and the risk of bleeding. Infections Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher infections occurred in 26% of patients, most commonly pneumonia (7.9%), with fatal infections occurring in 3.2% of patients. Infections due to hepatitis B virus (HBV) reactivation have occurred. Consider prophylaxis for herpes simplex virus, pneumocystis jirovecii pneumonia, and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately. Cytopenias Grade 3 or 4 cytopenias, including neutropenia (21%), thrombocytopenia (8%) and anemia (8%) based on laboratory measurements, developed in patients treated with BRUKINSA. Grade 4 neutropenia occurred in 10% of patients, and Grade 4 thrombocytopenia occurred in 2.5% of patients. Monitor complete blood counts regularly during treatment and interrupt treatment, reduce the dose, or discontinue treatment as warranted. Treat using growth factor or transfusions, as needed. Second Primary Malignancies Second primary malignancies, including non-skin carcinoma, have occurred in 14% of patients treated with BRUKINSA. The most frequent second primary malignancy was non-melanoma skin cancers (8%), followed by other solid tumors in 7% of the patients (including melanoma in 1% of patients) and hematologic malignancies (0.7%). Advise patients to use sun protection and monitor patients for the development of second primary malignancies. Cardiac Arrhythmias Serious cardiac arrhythmias have occurred in patients treated with BRUKINSA. Atrial fibrillation and atrial flutter were reported in 4.4% patients treated with BRUKINSA, including Grade 3 or higher cases in 1.9% of patients. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher ventricular arrhythmias were reported in 0.3% of patients. Monitor for signs and symptoms of cardiac arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea, chest discomfort), manage appropriately, and consider the risks and benefits of continued BRUKINSA treatment. Hepatotoxicity, Including Drug-Induced Liver Injury Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including BRUKINSA. Evaluate bilirubin and transaminases at baseline and throughout treatment with BRUKINSA. For patients who develop abnormal liver tests after BRUKINSA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold BRUKINSA. Upon confirmation of DILI, discontinue BRUKINSA. Embryo-Fetal Toxicity Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity, including malformations at exposures that were 5 times higher than those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for 1 week after the last dose. Advise men to avoid fathering a child during treatment and for 1 week after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Adverse Reactions The most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA (N=1729) are decreased neutrophil count (51%), decreased platelet count (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%). Drug Interactions CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily. CYP3A Inducers: Avoid coadministration with strong or moderate CYP3A inducers. Dose adjustment may be recommended with moderate CYP3A inducers. Specific Populations Hepatic Impairment: The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily. Please see full U.S. Prescribing Information including U.S. Patient Information. This information is intended for a global audience. Product indications vary by region. About BeOne BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding physicians and patients trust in BRUKINSA; whether the new tablet formulation for BRUKINSA will result in better patient experience; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. To access BeOne media resources, please visit our News & Media site.
Yahoo
10 hours ago
- Yahoo
New Mississippi laws go into effect on July 1
JACKSON, Miss. (WJTV) – July 1 may seem inconsequential for some, but it is a major day for change in Mississippi politics. This year, the day marks the start of a new term for many municipal officeholders. But each year in Mississippi, the first day of July is when many laws go into effect. Though this year's legislative session may have been unconventional by most metrics, the importance of July 1 remained the same in Mississippi. From kratom to college athletes, legislation passed in the 2025 legislative session will soon be felt across the state. Below is an overview of the most noteworthy bills in Mississippi. Kratom is a largely unregulated substance marketed as a pain reliever, anti-depressant and anxiety remedy with effects that mirror opiates at higher doses. The U.S. Food and Drug Administration reported that it is unsafe for use. The substance often for sale at gas stations across Mississippi is not banned by HB 1077, but its sale is restricted to those over the age of 21 starting on July 1. Some cities have banned kratom products. Current or future bans by municipalities or counties are permitted and enforceable under the new law. HB 1896, also passed this session, imposes a 25% excise tax on kratom sold within the state starting on July 1. For those wanting alcohol sent to their house, this bill authorizes the delivery of wine in Mississippi. To do so in Mississippi, a special permit for distributors is required. Additionally, a person at least 21-years-old or older must sign for any wine upon delivery. The bill establishes the Division of Autism Services within the state department of mental health. It will develop and coordinate services for individuals with autism spectrum disorder and their families. According to a 2024 report from the Mississippi Department of Mental Health, over 2% of Mississippi children aged three to seventeen years old have the condition. NCAA settlement could reshape Mississippi sports After the 2024 legislative session, the U.S. Supreme Court upheld an Oregon city's ordinances outlawing homeless encampments. For 2025, the Mississippi legislature passed a statewide law. The law, set to go into effect on July 1, will outlaw similar campsites from appearing unless explicitly permitted by public authorities. Punishments range up to a $500 fine and six months in jail. With the rapidly changing landscape of college athletics, the bill seeks to adjust to its biggest development: athlete pay. The law will allow schools to directly pay college athletes. It also enables institutions to help athletes make money off of their name, image and likeness. However, restrictions related to how student-athletes may market themselves remain in place. Bills that went into effect upon passage have also made headlines. HB 1193, which prohibits diversity, equity and inclusion practices at public institutions, went into effect upon passage. It is currently being challenged in court. HB 1, which will gradually eliminate the state's income tax, will take several years to come to fruition. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
